The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
fda pi zhun myalept yong yu zhi liao han jian dai xie xing ji bing
Pages: 194
Year: Issue:  3
Journal: World Clinical Drugs

Keyword:  代谢性疾病FDAMyalept脂肪代谢障碍脂肪组织瘦素水平类似物后天获得性高甘油三酯血症肥胖症患者;
Abstract: <正>近日,美国FDA批准注射用美曲普汀(metreleptin,Myalept)作为瘦素缺乏的替代性治疗药物,用于先天性或获得性全身脂肪代谢障碍患者的并发症治疗。全身脂肪代谢障碍是一种与脂肪组织缺乏有关的病症。先天性全身脂肪代谢障碍患者出生时脂肪组织很少或根本没有。后天获得性全身脂肪代谢障碍患者通常随着时间的推移脂肪组织流失。因瘦素由脂肪组织分泌,所以全身脂肪代谢障碍患者的瘦素水平很低。瘦素可调控进食及胰岛素等激素水平。本品为重组瘦素类似物,一项标签开放性试验评
Related Articles
No related articles found